Matthew Brams - 16 Jul 2026 Form 4 Insider Report for Cingulate Inc. (CING)

Reporting relationship: EVP and Chief Medical Officer
Issuer ticker: CING
Reported as of: 16 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Jul 2026, 19:32:12 UTC
Prior SEC filing: 11 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Shane J. Schaffer, Attorney-in-Fact

Key filing fact

Matthew Brams filed Form 4 for Cingulate Inc. (CING) on 20 Jul 2026.

Key facts

This page summarizes Matthew Brams's Form 4 filing for Cingulate Inc. (CING).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 20 Jul 2026, 19:32.

Change

Previous filing in this sequence was filed on 11 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001884361 Primary reporting owner

Brams Matthew

Relationship: EVP and Chief Medical Officer
Address: 1901 W. 47TH PLACE, KANSAS CITY
Signature: /s/ Shane J. Schaffer, Attorney-in-Fact
Signature date: 20 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CING transaction Derivative

Stock Option (right to Buy)

Award

Transaction value
Shares: +53,600
Change %
Price: $0.000000^*
Shares after: 53,600
Date: 16 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 53,600
Exercise price: $4.43
Footnotes: F1

CING transaction Derivative

Stock Option (right to Buy)

Award

Transaction value
Shares: +26,400
Change %
Price: $0.000000^*
Shares after: 26,400
Date: 16 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,400
Exercise price: $4.43
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date.

Footnote F2

Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved by the FDA during 2027.

Footnote F3

If the Issuer's NDA for CTx-1301 is not approved by the FDA during 2027, the option, including any vested portion, shall terminate.